Tugan Tezcaner

Tugan Tezcaner

Auto-generated profile, based on publicly available information

Tugan Tezcaner

From the Department of General Surgery, Başkent University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2015 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
Massimo SartelliMassimo Sartelli
Massimo Sartelli
FAFikri M Abu-Zidan
Fikri M Abu-Zidan
Fausto CatenaFausto Catena
Fausto Catena
EGEwen Griffiths
Ewen Griffiths
Salomone Di SaverioSalomone Di Saverio
Salomone Di Saverio
LALuca Ansaloni
Luca Ansaloni
To validate a new practical Sepsis Severity Score for patients with complicated intra-abdominal infections (cIAIs) including the clinical conditions at the admission (severe sepsis/septic shock), the origin of the cIAIs, the delay in source control, the setting of acquisition and any risk factors such as age and immunosuppression. The WISS study (WSES cIAIs Score Study) is a multicenter observational study underwent in 132 medical institutions worldwide during a four-month study period (October 2014-February 2015). Four thousand five hundred thirty-three patients with a mean age of 51.2 years (range 18–99) were enrolled in the WISS study. Univariate analysis has shown that all factors that were previously included in the WSES Sepsis Severity Score were highly statistically significant between those who died and those who survived (p < 0.0001). The multivariate logistic regression model was highly significant (p < 0.0001, R2 = 0.54) and showed that all these factors were independent in predicting mortality of sepsis. Receiver Operator Curve has shown that the WSES Severity Sepsis Score had an excellent prediction for mortality. A score above 5.5 was the best predictor of mortality having a sensitivity of 89.2 %, a specificity of 83.5 % and a positive likelihood ratio of 5.4. WSES Sepsis Severity Score for patients with complicated Intra-abdominal infections can be used on global level. It has shown high sensitivity, specificity, and likelihood ratio that may help us in making clinical decisions.

21 February 2017 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
ACand Federico Coccolini
and Federico Coccolini
GMGiulia Montori
Giulia Montori
MCMarco Ceresoli
Marco Ceresoli
Fausto CatenaFausto Catena
Fausto Catena
RIRao Ivatury
Rao Ivatury
LALuca Ansaloni
Luca Ansaloni
No definitive data about open abdomen (OA) epidemiology and outcomes exist. The World Society of Emergency Surgery (WSES) and the Panamerican Trauma Society (PTS) promoted the International Register of Open Abdomen (IROA). A prospective observational cohort study including patients with an OA treatment. Data were recorded on a web platform (Clinical Registers®) through a dedicated website: www.clinicalregisters.org . Four hundred two patients enrolled. Adult patients: 369 patients; Mean age: 57.39±18.37; 56% male. OA indication: Peritonitis (48.7%), Trauma (20.5%), Vascular Emergencies/Hemorrhage (9.4%), Ischemia (9.1%), Pancreatitis (4.2%),Post-operative abdominal-compartment-syndrome (3.9%), Others (4.2%). The most adopted Temporary-abdominal-closure systems were the commercial negative pressure ones (44.2%). During OA 38% of patients had complications; among them 10.5% had fistula. Definitive closure: 82.8%; Mortality during treatment: 17.2%. Mean duration of OA: 5.39(±4.83) days; Mean number of dressing changes: 0.88(±0.88). After-closure complications: (49.5%) and Mortality: (9%). No significant associations among TACT, indications, mortality, complications and fistula. A linear correlationexists between days of OA and complications (Pearson linear correlation = 0.326 p<0.0001) and with the fistula development (Pearson = 0.146 p= 0.016). Pediatric patients: 33 patients. Mean age: 5.91±(3.68) years; 60% male. Mortality: 3.4%; Complications: 44.8%; Fistula: 3.4%. Mean duration of OA: 3.22(±3.09) days. Temporary abdominal closure is reliable and safe. The different techniques account for different results according to the different indications. In peritonitis commercial negative pressure temporary closure seems to improve results. In trauma skin-closure and Bogotà-bag seem to improve results. ClinicalTrials.gov NCT02382770

1 April 2015 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
MKMahir Kırnap
Mahir Kırnap
TTTugan Tezcaner
Tugan Tezcaner
HSHatice Ebru Ayvazoğlu Soy
Hatice Ebru Ayvazoğlu Soy
AAAydıncan Akdur
Aydıncan Akdur
SYSedat Yıldırım
Sedat Yıldırım
MHMehmet Haberal
Mehmet Haberal
Liver transplant currently is the best treatment option for end-stage liver disease. During liver transplant, there is major blood loss due to surgery and primary disease. By using a cell saver, the need for blood transfusion is markedly reduced. In this study, we aimed to evaluate the efficacy of cell saver use on morbidity and mortality in living-donor liver transplant. We retrospectively evaluated 178 living-donor liver transplants, performed from 2005 to 2013 in our center. Child-Turcotte-Pugh A patients, deceased-donor liver transplants, and liver transplants performed for fulminant hepatic failure were not included in this study. Intraoperative blood transfusion was done in all patients to keep hemoglobin level between 10 and 12 g/dL. Cell saver was used in all liver transplants except in patients with malignancy, hepatitis B, and hepatitis C. We included 126 patients in the study. Cell saver was used in 84 liver transplants (66%). In 42 patients (34%), liver transplant was performed without a cell saver. In living-donor liver transplant with cell saver use, 10 mL/kg blood (range, 2-50 mL/kg blood) was transfused from the cell saver; in addition, 5 to 10 mL/kg allogeneic blood was transfused. In living-donor liver transplant without cell saver, 20 to 25 mL/kg allogeneic blood was transfused. During liver transplant, major blood transfusion is needed because of surgery and primary disease. Cell saver use markedly decreases the need for allogeneic blood transfusion and avoids adverse events of massive transfusion.

1 January 2005 in Journal of Investigative Surgery
Verified
Journal Article
Closed access
NANusret Akyürek
Nusret Akyürek
BSBülent Salman
Bülent Salman
OIOktay Irkörücü
Oktay Irkörücü
TTTugan Tezcaner
Tugan Tezcaner
CACem Azili
Cem Azili
ETErtan Tatlicioglu
Ertan Tatlicioglu
Expression of intracellular adhesion molecule-1 (ICAM-1) in an obstructive jaundice model and the potential protective role of platelet activating factor antagonist over small intestine and liver together with its effects on bacterial translocation are examined in this study. Forty-eight male Wistar albino rats were assigned into four equal groups of 12. In groups I and II, animals were sham operated. In groups III and IV, common bile duct ligation and division were performed. In group I and group III, 0.5 ml/day normal saline was applied intraperitoneally daily from day 2 to 6 of the study; in group II and group IV, 1 mg/kg/day BN 52021 was applied intraperitoneally daily from day 2 to 6 of the study. All animals were sacrificed on postoperative day 7. ICAM-1 expression (CD54 positivity) was analyzed in the liver and ileum tissue by immunohistochemical method. Samples from blood, liver mesenteric lymph nodes, and spleen were cultured under aerobic conditions. It is revealed that ICAM-1 expression was statistically higher in group III, with highest bacterial translocation and liver and spleen injury when compared to other groups. Serum alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (GGT), bilirubin, tumor necrosis factor alpha (TNFalpha), and interleukin 1beta(IL-1beta) values were at the highest level in group III, and there was a statistical decrease in group IV compared to group III. The administration of BN52021 in experimental obstructive jaundice is a useful way to reduce liver and intestinal mucosal villi damage by inhibiting bacterial translocation and systemic inflammatory response.

1 October 2019 in European Journal of Breast Health
Verified
Journal Article
Closed access
STSehnaz Tezcan
Sehnaz Tezcan
NUNihal Uslu
Nihal Uslu
FOFunda Ulu Ozturk
Funda Ulu Ozturk
EAEda Yilmaz Akcay
Eda Yilmaz Akcay
TTTugan Tezcaner
Tugan Tezcaner
Eur J Breast Health AVES | Copyright © 2017 Türkiye Meme Hastalıkları Dernekleri Federasyonu |

1 April 2015
Verified
Journal Article
Closed access
GMGökhan Moray
Gökhan Moray
TTTugan Tezcaner
Tugan Tezcaner
AAAydıncan Akdur
Aydıncan Akdur
FÖFigen Özçay
Figen Özçay
ASAtilla Sezgin
Atilla Sezgin
MHMehmet Haberal
Mehmet Haberal